BRAF and malignant colon neoplasm: Together, we showed feedback HER3 activation upon cetuximab treatment in KRAS and BRAF colon cancer cells together with induction of HER2:HER3 heterodimers, which could potentially result in cetuximab resistance in colorectal cancer patients.